GIC Private and BlackRock have joined four other investors to cornerstone Chinese biotech pharmaceutical developer 3SBio's relisting in Hong Kong, two years after it was taken off NASDAQ...
Greater China | 28 May 2015 |
ChrysCapital Partners has sold its 11% stake in India-based Mankind Pharma to investment firm Capital International for just over $200 million, valuing the company at about $2.2 billion.
South Asia | 28 May 2015 |
A consortium of Chinese investors including Shanghai Fosun Pharmaceutical Group, Hopu Investments, CEL Healthcare Fund and WuXi PharmaTech will acquire Ambrx, a US-based biotech pharmaceutical developer.
Greater China | 22 May 2015 |
Hony Capital CEO John Zhao expects to see more control opportunities arising from domestic succession planning, cross-border expansion and restructuring. He explains how his firm is preparing the ground
Buyouts | 20 May 2015
Private equity investors see huge opportunities in China’s hospital space on the back of healthcare reforms. But valuations are high, doctors are in limited supply, and regulation can be a headache
Buyouts | 20 May 2015 |
BeiGene, a Chinese company that develops drugs to combat cancer, has raised RMB600 million ($97 million) in a funding round led by existing investors Hillhouse Capital and an undisclosed US-based life sciences-focused public investment fund.
Greater China | 14 May 2015 |
Taiwan-based biopharmaceutical company JHL Biotech has raised a $45 million Series C round, led by an unnamed investor. Existing backer Milestone Capital also participated, along with newcomers Sungent BioVenture and Liwick Investment Management.
Greater China | 14 May 2015 |
CLSA Capital Partners (CLSA CP) has invested RMB150 million ($24.5 million) in Coco Healthcare Products, a Chinese manufacturer of diapers for adults and babies. It plans to help the company boost its export business.
Greater China | 13 May 2015 |
South Korea-based Posco Capital and biopharmaceutical player Green Cross have led a $7.5 million round for Juventas Therapeutics, a clinical-stage biotech development company based in the US.
South Asia | 13 May 2015 |
Inner Mongolia FuRui Medical Science (FuRui) started out two decades ago as a pure-play drug manufacturer, but then it found its niche developing diagnostic equipment and treatment for liver disease. Looking to bring in overseas technology, it acquired...
Healthcare | 06 May 2015 |
WuXi PharmaTech, a China-based provider of contract R&D services to the global pharmaceutical sector, has received a take-private bid led by its founder and chairman and healthcare-focused PE firm Ally Bridge Group.
Buyouts | 04 May 2015 |
India's Fortis Healthcare will sell its Singapore-based diagnostics arm RadLink-Asia to Fullerton Healthcare Group for S$111 million ($83.5 million).
South Asia | 04 May 2015 |
Cathay Capital has led a EUR30 million ($33 million) round of funding for Echosens, a France-based diagnostic medical device manufacturer owned by China’s Inner Mongolia FuRui Medical Science.
Greater China | 30 Apr 2015 |
Yunfeng Capital, Shenzhen Cowin Capital, New Horizon Capital and Hunan Haijie Healthcare Investment have provided RMB200 million ($32 million) in Series B funding for Huakang Mobile Healthcare, a Chinese mobile healthcare app developer.
Greater China | 29 Apr 2015 |
China Cord Blood, a US-listed blood banking operator in which KKR holds a minority stake, has received a take-private offer from its largest shareholder, Chinese healthcare company Golden Meditech.
Exits | 29 Apr 2015 |
Updating your subscription status
In 2015, China is expected to experience a "new normal of growth". For private equity investors, China's new stage of growth represents huge opportunities: an increase of 270% in online consumption, the reform of over a hundred sovereign-owned enterprises, trillion-dollar investments into overseas infrastructure projects, the rising entrance of young entrepreneurs, and many more.
To be held on 28 and 29 May, the 14th annual AVCJ China Forum 2015 in Beijing will feature these exciting topics and bring together top-notch speakers from across the world.Join the premium industrial gathering of over 300 private equity professionals, regulators and senior executives for two days of mind-provoking discussions, networking and more.
28-29 May 2015, China World Summit Wing,Beijing
There is a feeling that now is a shrewd time to invest in Japan and take advantage of the favourable conditions for private equity. Valuations are low compared with the rest of Asia and strategic buyers and the IPO market are providing an attractive route for exits. There are also signs that corporate Japan is slowly coming around to engaging PE as a potential buyer for non-core assets and recent developments at the GPIF suggest that PE will be under strong consideration for allocations from pension funds in the near future as well as regional banks committing to the asset class right now.
The macro concerns that have been present for many years still remain in terms of low growth and currency depreciation but these are encouraging times for fund managers looking to both raise capital from Japanese LPs and make investments.
245-26 June 2015, Conrad Hotel, Tokyo